William Hoffman - 09 Sep 2022 Form 4 Insider Report for Inari Medical, Inc.

Role
President and CEO, Director
Signature
/s/ Angela Ahmad, attorney-in-fact for William Hoffman
Issuer symbol
N/A
Transactions as of
09 Sep 2022
Net transactions value
-$1,054,475
Form type
4
Filing time
12 Sep 2022, 19:28:50 UTC
Previous filing
09 Sep 2022
Next filing
04 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NARI Common Stock Sale $150,169 -1,984 -0.55% $75.69 360,609 09 Sep 2022 Direct F1, F2
transaction NARI Common Stock Sale $424,879 -5,533 -1.5% $76.79 355,076 09 Sep 2022 Direct F1, F3
transaction NARI Common Stock Sale $479,427 -6,175 -1.7% $77.64 348,901 09 Sep 2022 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2021.
F2 This transaction was executed in multiple trades at prices ranging from $75.18 to $76.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $76.31 to $77.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $77.33 to $78.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.